# Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function

> **NCT00275093** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 130 (actual)

## Conditions studied

- Hepatic Complications
- Lymphoma
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** temsirolimus
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00275093
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-03
- **Final completion:** —
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2013-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00275093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00275093, "Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00275093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*